Drugs / Zepatier

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Zepatier 2016-07-22 europa.eu
Approved US (FDA) ZEPATIER 2016-01-28 fda.gov

Trials 5 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT03724149 Dec 2018 → Dec 2021 lung disorder University of Pennsylvania Completed No outcome recorded
Phase 1/2 NCT02743897 May 2016 → Mar 2022 end stage renal failure University of Pennsylvania Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT02115321 May 2014 → Mar 2015 chronic hepatitis C virus infection Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 42 trials
Phase 4 NCT03093740 Oct 2018 → Dec 2020 chronic renal failure syndrome, hepatitis C virus infection Massachusetts General Hospital Withdrawn No outcome recorded
Phase 4 NCT03093415 May 2017 → Jun 2019 hepatitis C virus infection, substance abuse Oregon Health and Science University Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Zepatier ClinicalTrials.gov intervention name — accepted as the source's own label NCT02743897
2

NCT03724149

NCT03093740

Known as elbasvir-grazoprevir ClinicalTrials.gov intervention name — accepted as the source's own label NCT03093415
Known as MK-5172A ClinicalTrials.gov intervention name — accepted as the source's own label NCT02115321
Modality Other / unclassified “Direct-acting antiviral treatment for HCV” NCT02743897
Route Oral “MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.” NCT02115321